Spots Global Cancer Trial Database for splenomegaly
Every month we try and update this database with for splenomegaly cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma | NCT05992532 | Gaucher Disease Acid SphingoMye... | 18 Years - 99 Years | Fundación Española de Hematología y Hemoterapía | ||
| MPN-RC 118 AVID200 in Myelofibrosis | NCT03895112 | Primary Myelofi... Post-essential ... Post-polycythem... Post ET MF Post PV MF | AVID200 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | NCT02421354 | Hepatomegaly Myelofibrosis T... Polycythemia Ve... Primary Myelofi... Splenomegaly | Laboratory Biom... Nivolumab Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | NCT02421354 | Hepatomegaly Myelofibrosis T... Polycythemia Ve... Primary Myelofi... Splenomegaly | Laboratory Biom... Nivolumab Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Incentive Spirometry and Upper Abdominal Laparoscopic Surgery | NCT04716166 | Cholecystitis Perforated Duod... Diaphragmatic H... Benign Pancreas... Malignant Pancr... Splenic Infarct... Splenomegaly Choledocholithi... Hiatal Hernia | Volume-oriented... Flow-oriented i... | 25 Years - 65 Years | Riphah International University | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | NCT02948283 | Anemia Fatigue Fever Lymphadenopathy Lymphocytosis Night Sweats Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Plas... Splenomegaly Thrombocytopeni... Weight Loss | Laboratory Biom... Metformin Hydro... Pharmacological... Ritonavir Quality-of-Life Questionnaire | 18 Years - | City of Hope Medical Center | |
| Oxaliplatin-induced Portal Hypertension | NCT04524676 | Gastroesophagea... Colorectal Canc... Received Oxalip... | Individualized ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
